<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516774</url>
  </required_header>
  <id_info>
    <org_study_id>2014-002618-22</org_study_id>
    <secondary_id>2014/2142</secondary_id>
    <nct_id>NCT02516774</nct_id>
  </id_info>
  <brief_title>A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers</brief_title>
  <acronym>TAM-RT</acronym>
  <official_title>A Phase I Trial Assessing Adalimumab (Humira®), a Tumor Necrosis Factor α Inhibitor Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that the particular richness of ATC's microenvironment in TAMs creates a
      unique opportunity for using Tumor Necrosis Factor blockade during chemotherapy and
      radiotherapy in order to counteract tumor resistance to therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No patients enrolled
  </why_stopped>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended dose</measure>
    <time_frame>Up to 9 weeks</time_frame>
    <description>Two dose levels will be investigated :
Level 1: 20 mg at D1W1, D1W3, D1W5, D1W7 and D1W9.
Level 2: 40 mg at D1W1, D1W3, D1W5, D1W7 and D1W9.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Anaplastic Thyroid Cancers</condition>
  <arm_group>
    <arm_group_label>Dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab will be administrated subcutaneously 1h prior to chemotherapy at D1W1, D1W3, D1W5, D1W7, and D1W9, starting with the chemotherapy for a total duration of 9 weeks (5 injections in total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <arm_group_label>Dose escalation</arm_group_label>
    <other_name>Humira®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically proven anaplastic thyroid cancers (localized or metastatic)

          2. Life-expectancy &gt; 12 weeks

          3. No previous treatment for anaplastic thyroid cancer excepted surgery or crizotinib

          4. Written Informed consent signed

          5. Age &gt; 18 years

          6. WHO 0-3

          7. Neutrophil count &gt; 1500 /mm3, Haemoglobin &gt; 9 gr/dL, Platelet count &gt; 100,000/mm3

          8. Bilirubin &lt; 1.5 mg/dL, Transaminases &lt; 3 N in absence of liver metastases or &lt;5 N if
             presence of liver metastases, PT &gt; 70%

          9. Creatinine clearance &gt; 50ml/mn (calculated by the MDRD formula)

         10. Negative pregnancy test in women of childbearing potential within 14 days prior to
             treatment initiation (premenopausal or less than 12 months of amenorrhea
             post-menopause, and who have not undergone surgical sterilization). Both men and women
             (of childbearing potential) who are sexually active, must use adequate contraception,
             during and for at least 6 months post-treatment.

         11. Evaluable disease &gt; 1 cm within the cervico-mediastinal field of radiotherapy
             according to the Response Evaluation Criteria in Solid Tumors 1.1 criteria

         12. Patient affiliated to social security regimen or beneficiary of such regimen

        Exclusion Criteria:

          1. Prior treatment with anthracyclines

          2. Left Ventricular Ejection Fraction (LVEF) &lt; 50%

          3. Known allergy to Adalimumab, doxorubicin, cisplatin, carboplatin or paclitaxel

          4. Chronic or acute infection &lt; 15 days

          5. Pregnant or breastfeeding patients

          6. Any other malignancy in the past 5 years except basal cell carcinoma and carcinoma in
             situ of the cervix

          7. Previous and/or active demyelinating disease, such as multiple sclerosis

          8. Prior radiotherapy to the neck

          9. Concomitant therapy with agents otherwise used in the treatment of cancer (for example
             methotrexate for rheumatoid arthritis)

         10. Chronic (&gt; 3 months) treatment with oral corticosteroids or another immunosuppressant
             within 15 days prior registration

         11. Patients with an active bleeding diathesis or taking an oral vitamin K antagonist
             (except low-dose Coumadin (warfarin sodium))

         12. Other concurrent severe and/or uncontrolled disease which could compromise
             participation in the study (i.e. uncontrolled diabetes, uncontrolled hypertension,
             severe infection, severe malnutrition, unstable angina, or congestive heart failure -
             New York Heart Association Class III or IV, ventricular arrhythmia, active ischemic
             heart disease, myocardial infarction during the previous six months, chronic liver or
             renal disease, active upper GI tract ulceration)

         13. Patient already enrolled in another therapeutic trial involving an investigational
             substance, and when such a substance has been taken during the previous 4 weeks

         14. Chronic Hepatitis B virus and previous viral hepatitis with risk of reactivation,
             Hepatitis C virus and human immunodeficiency virus 1 or human immunodeficiency virus 2
             infection, active or latent tuberculosis infection

         15. Persons deprived of their freedom or under guardianship, or for whom it would be
             impossible to undergo the medical follow-up required by the trial, for geographic,
             social or psychological reasons Refusal or absence of biopsy (excepted for initial
             pathological diagnosis) will not constitute an exclusion criterion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>January 25, 2016</last_update_submitted>
  <last_update_submitted_qc>January 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Carcinoma, Anaplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

